Overview

Cobimetinib In Extracranial Arteriovenous Malformations (COBI-AVM Study)

Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this open-label study is to evaluate the safety and efficacy of cobimetinib in extracranial AVM.
Phase:
Phase 2
Details
Lead Sponsor:
University of Arkansas
Collaborator:
Genentech, Inc.